Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

Stifel analyst Annabel Samimy has reaffirmed a Buy rating on MBX Biosciences (NASDAQ: MBX) and increased the price target from $70 to $84. This adjustment reflects a positive outlook for the company in the market.